Electrochemical Immunosensor for Simultaneous Detection of Dual Cardiac Markers Based on a Poly(Dimethylsiloxane)-Gold Nanoparticles Composite Microfluidic Chip: A Proof of Principle

Zhou, Fang; Lu, Minghui; Wang, Wei; Bian, Zhiping; Zhang, Jian‐Rong; Zhu, Jun‐Jie

doi:10.1373/clinchem.2010.147256

Cited by 125 publications

(36 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The past decade has witnessed great progress in developing various detection devices, especially those coupled with microfluidics. 231 These platforms may soon enable accurate detection of panels of biomarkers of interest in various clinical samples. It is not surprising that the detection results of any nanosensor are sensitive to the size, shape, composition of nanomaterials, or bioconjugation efficiency during the preparation of tags.…”

Section: Aunp-based Electrochemical Assaysmentioning

confidence: 99%

Gold Nanoparticles for In Vitro Diagnostics

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Aunp-based Electrochemical Assaysmentioning

confidence: 99%

Gold Nanoparticles for In Vitro Diagnostics

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Multiple microfluidic electrochemical systems were developed to measure heart disease biomarkers. Zhou et al 134 developed an electrochemical immunoassay for the simultaneous detection of cardiac cTnI and c-reactive protein (CRP) on a PDMS microfluidic chip. Cardiac troponin I is used to diagnose acute myocardial infarction.…”

Section: Biomarker Detection Methods For Disease Diagnosis Using Mmentioning

confidence: 99%

Biomarker detection for disease diagnosis using cost-effective microfluidic platforms

Sanjay

Dou

et al. 2015

Analyst

224

171

View full text Add to dashboard Cite

Early and timely detection of disease biomarkers can prevent the spread of infectious diseases, and drastically decrease the death rate of people suffering from different diseases such as cancer and infectious diseases. Because conventional diagnostic methods have limited application in low-resource settings due to the use of bulky and expensive instrumentation, simple and low-cost point-of-care diagnostic devices for timely and early biomarker diagnosis, is the need of the hour, especially in rural areas and developing nations. The microfluidics technology possesses remarkable features for simple, low-cost, and rapid disease diagnosis. There have been significant advances in the development of microfluidic platforms for diseases biomarker detection. This article reviews recent advances in biomarker detection using cost-effective microfluidic devices for disease diagnosis, with the emphasis on infectious disease and cancer diagnosis in low-resource settings. This review first introduces different microfluidic platforms (e.g. polymer and paper-based microfluidics) used for disease diagnosis, with a brief description of their common fabrication techniques. Then, it highlights various detection strategies for disease biomarker detection using microfluidic platforms, including colorimetric, fluorescence, chemiluminescence, electrochemiluminescence (ECL), and electrochemical detection. Finally, it discusses the current limitations of microfluidics devices for disease biomarker detection and the future perspectives.

show abstract

“…Other cardiovascular disease biomarkers are also quantified. CRP measurement rely mainly on immunosensing technologies with optical, electrochemical and acoustic transducers besides approaches to simultaneous analytes measurement (Albrecht et al, 2008;Heyduk et al, 2008;McBride & Cooper, 2008;Niotis et al, 2010;Qureshi et al, 2010a,b;Sheu et al, 2010;Zhou et al, 2010). Silva et al (2010) incorporated streptavidin polystyrene microspheres to the electrode surface of SPEs in order to increase the analytical response of the cardiac troponin T and Park et al (2009) used an assay based on virus nanoparticles for troponin I highly sensitive and selective diagnostic, a protein marker for a higher risk of acute myocardial infarction.…”

Section: Biosensors In Cardiovascular Diseasementioning

confidence: 99%